current user: public
If you have questions about the server, please let us know.

Query: PF08626.11; C0NZX0_AJECG/5-1447; Transport protein Trs120 or TRAPPC9, TRAPP II complex subunit, from PfamA32U

Results of FFAS03 search in PfamA32U
Master-slave alignment(slide right to see more) does not show gaps in the query sequence, use ali links to display alignment between query and templates.
    .   10    .   20    .   30    .   40    .   50    .   60    .   70    .   80    .   90    .  100    .  110    .  120    .  130    .  140    .  150    .  160    .  170    .  180    .  190    .  200    .  210    .  220    .  230    .  240    .  250    .  260    .  270    .  280    .  290    .  300    .  310    .  320    .  330    .  340    .  350    .  360    .  370    .  380    .  390    .  400    .  410    .  420    .  430    .  440    .  450    .  460    .  470    .  480    .  490    .  500    .  510    .  520    .  530    .  540    .  550    .  560    .  570    .  580    .  590    .  600    .  610    .  620    .  630    .  640    .  650    .  660    .  670    .  680    .  690    .  700    .  710    .  720    .  730    .  740    .  750    .  760    .  770    .  780    .  790    .  800    .  810    .  820    .  830    .  840    .  850    .  860    .  870    .  880    .  890    .  900    .  910    .  920    .  930    .  940    .  950    .  960    .  970    .  980    .  990    . 1000    . 1010    . 1020    . 1030    . 1040    . 1050    . 1060    . 1070    . 1080    . 1090    . 1100    . 1110    . 1120    . 1130    . 1140    . 1150    . 1160    . 1170    . 1180    . 1190    . 1200    . 1210    . 1220    . 1230    . 1240    . 1250    . 1260    . 1270    . 1280    . 1290    . 1300    . 1310    . 1320    . 1330    . 1340    . 1350    . 1360    . 1370    . 1380    . 1390    . 1400    . 1410    . 1420    . 1430    . 1440
# Score Template Links and tools%idFirst PLSPVAPARLRALLLPVGNIKRSRFLNLVKRLQDQNVVRLGDVSPDCRPNRNAFSPMAFPTGMIVYDLSISVPPISHLDLYPFEIFREPLVIIAIADGTELPGPPEGTGTYSQTQSNGTKPCNYPTVEGLQLLQQELNTLKDSHPKSLVQQLLVFDYAAVSKLVTGPDTVIWVPRPEAARSTTVKTVMCDITSRLLGELSGLAERIQEWPTVESPKASSWGPRRKPEVRPPVSEKLQHRMTMPAQLPGANGTFVDASDTNFQPAEHDSPTTFDEITRSIQVSNRVTSSIKASSKPGSKEHSRERMSAQGLGFVAASERSKSRVKGRLNIVMGTLFLQAGRWPDSLKELAEGATIARANSDYIWHAKALESILQCLLMLGWAGMDFRIPQICYPTADKFSKSVSQTPSLSHTELYSIGQSNPENRRVSLQNLANLLPDLANNILNLYTRAANITDEPVPQLVFSETVIRLARILATVYIRDGSLDDSALGNIVMNDSLKFVRSQERPRGTVSLRKSDIASFLFRALPASLGTDVPITDSTPILVGMASVLSSLGLDRKNAFVLQLLFSILIPGLVQARKIGAAEVGIHPAAGLSALNYSAFEMNALDAGPGNMEESIRILLALVGKIYGVPGIMICTDNRRDLSRHNSTAKSETVPEYDSVDSIVDRAFRHSVMNGFGDHTLKVEILKACINLCEALPDFQGVLQFTVDLLQTVKGTLMLLPDSYLGLPVIPLQEQVRLFNNVKRTVAAAKKLGDSNLEAEYWDDFMVRGVELVNSSDFKSPVRRSRTDFGFANVEERLEKKNPFIYSTFSKATTKRSEDLLIAEEPATFKVTLQNPFEFDVEIESLRIDGTGIPFEAAATHGLWLAPFTTQEYYISGVAATEGTLEIRGCTVKVKFCRERIFPIFKNFWKPQKEQKIKRTGLAAKEPFSERPLSWSSNASRSRLGASRKGPEPDIVLIKVIQKQPTVIIHSTSLSQSAIMLLEGETRSFDITLQNISTCPLDFISFSFEDSSTPQLQSALNNKENLPTDMYELELRLSTNPAMTWRRDKLHDYELSIAPGETATFTIDIYGKPGLDNAILKIDYANVCTSLADLPETFYCRQISLPLTVTVNAGVDVTRCDVLPFTSDFAWDNNKLQQSEDSRTSLGDKEAIKSMESSSTPRSITQFREAQFSQTFSRIGLSSFGFGHCLLLLDLRNAWPNPLTVSLFVNENISDGAKSPDDKLKHNPVGIHEIFDELQPGHISRFLLVVPRVYIENAQKPIPSLNVSNKRQFVVSANKLDYEAESSARECFWFREELLKHLRGSWKDVATGRGGVIDLRAIRLNARMVDALRIDDADVTFSLRPYTGDSSNDKTIENGIDSVSQTGHSKFTVKTNTFLTLSATIINRSSKPIHPLLRLQPSLRHTPHAIALDLSKRLAWSGMLQRALPILEPHQTTEVTLGVLast
1 -389.000PF08626.11; C0NZX0_AJECG/5-1447; Transport protein Trs120 or TRAPPC9, TRAPP II complex subunit  ali  100  1PLSPVAPARLRALLLPVGNIKRSRFLNLVKRLQDQNVVRLGDVSPDCRPNRNAFSPMAFPTGMIVYDLSISVPPISHLDLYPFEIFREPLVIIAIADGTELPGPPEGTGTYSQTQSNGTKPCNYPTVEGLQLLQQELNTLKDSHPKSLVQQLLVFDYAAVSKLVTGPDTVIWVPRPEAARSTTVKTVMCDITSRLLGELSGLAERIQEWPTVESPKASSWGPRRKPEVRPPVSEKLQHRMTMPAQLPGANGTFVDASDTNFQPAEHDSPTTFDEITRSIQVSNRVTSSIKASSKPGSKEHSRERMSAQGLGFVAASERSKSRVKGRLNIVMGTLFLQAGRWPDSLKELAEGATIARANSDYIWHAKALESILQCLLMLGWAGMDFRIPQICYPTADKFSKSVSQTPSLSHTELYSIGQSNPENRRVSLQNLANLLPDLANNILNLYTRAANITDEPVPQLVFSETVIRLARILATVYIRDGSLDDSALGNIVMNDSLKFVRSQERPRGTVSLRKSDIASFLFRALPASLGTDVPITDSTPILVGMASVLSSLGLDRKNAFVLQLLFSILIPGLVQARKIGAAEVGIHPAAGLSALNYSAFEMNALDAGPGNMEESIRILLALVGKIYGVPGIMICTDNRRDLSRHNSTAKSETVPEYDSVDSIVDRAFRHSVMNGFGDHTLKVEILKACINLCEALPDFQGVLQFTVDLLQTVKGTLMLLPDSYLGLPVIPLQEQVRLFNNVKRTVAAAKKLGDSNLEAEYWDDFMVRGVELVNSSDFKSPVRRSRTDFGFANVEERLEKKNPFIYSTFSKATTKRSEDLLIAEEPATFKVTLQNPFEFDVEIESLRIDGTGIPFEAAATHGLWLAPFTTQEYYISGVAATEGTLEIRGCTVKVKFCRERIFPIFKNFWKPQKEQKIKRTGLAAKEPFSERPLSWSSNASRSRLGASRKGPEPDIVLIKVIQKQPTVIIHSTSLSQSAIMLLEGETRSFDITLQNISTCPLDFISFSFEDSSTPQLQSALNNKENLPTDMYELELRLSTNPAMTWRRDKLHDYELSIAPGETATFTIDIYGKPGLDNAILKIDYANVCTSLADLPETFYCRQISLPLTVTVNAGVDVTRCDVLPFTSDFAWDNNKLQQSEDSRTSLGDKEAIKSMESSSTPRSITQFREAQFSQTFSRIGLSSFGFGHCLLLLDLRNAWPNPLTVSLFVNENISDGAKSPDDKLKHNPVGIHEIFDELQPGHISRFLLVVPRVYIENAQKPIPSLNVSNKRQFVVSANKLDYEAESSARECFWFREELLKHLRGSWKDVATGRGGVIDLRAIRLNARMVDALRIDDADVTFSLRPYTGDSSNDKTIENGIDSVSQTGHSKFTVKTNTFLTLSATIINRSSKPIHPLLRLQPSLRHTPHAIALDLSKRLAWSGMLQRALPILEPHQTTEVTLGV 1443
2 -28.500PF07919.12; C4JTF4_UNCRE/662-1266; Gryzun, putative trafficking through Golgi  ali follow..  11  21.................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................RSEGNVGEPLLAQLVITSTAHEAIRLSEVIVAFEGSLRPMTGTVDLAFPPGQTKAFNLTCIPREAGKVQVTSITLMI---------------------EDEMFNLTSVISSQSFKDPVWWSPGIKGAISRRIGKDRDTITCDILPKPPKVRI---LTPTLHDHYYTDEHAVLDIQIENEEDEAAESIEARLLGQSEDSAQIHWVDDPEACVQPRDSSPTSPTDDSGSLGQVKRKEIG-ALDSGGRKAISLNVTNTSVPLEYGLEISAFYHLLSDPETP------FKTVTLDLPFIRPFEA-NYELMPRVHPGPWPDFFHVDEPKLIDESEPR--------------------------------AHGLQQRWCLDCKLISFAHETLLID-KVSVAVTGIEGGLVRHIGPEIHTGNVEAAELHPEQVRESQ-------------------------FILELQRLTLGDRQTTT--------LNLALEVKWRRQDAEAPSSSAVELFIPTTTLVPRFVIPMGEPRVLATVTR------------------------ASALPNFIHLDYTLENPSIHFLTFTITM-------------EASDQFAFSGPKSLAVQ-LVPLSRHTVRYNL 561
3 -13.200PF00927.22; EPB42_HUMAN/588-686; Transglutaminase family, C-terminal ig like domain  ali follow..  19  12.....................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................EQYQPLTASVSLQNSLDAPMEDCVISILGRGLIHRERSYRFRSVWPENTMCAKFQFTPTHVGLQRLT........................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 78
4 -12.000PF06159.13; J3KCX7_COCIM/67-339; Protein of unknown function (DUF974 topsan)  ali follow..  14  2............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................MLPPAFGSAYVGETFSCSLSANNDASRVVTSIRILAEMQTPSQVVPLELYPSSDDND----------------------TKSGGIAQVESMQKIVR-LKEEGNHVLAVGVSYTETMITPSSDAHGSVQRTFRKLYQFVAQPCLNVR--------------------------------------------TKATELPPQEVDNRSLGPYGKTKLYRFALEAQLENVGDGIITLG-AVTLNPKPPFKSRSLNWDFESSADKESIPTLSPRDVLQIAFIVE------------------------QEHGQQDGLETLQKDMNREGRATLGQLSLEWR-SALGDRGFLTTGNL......................................................................................................................... 271
5 -11.900PF12739.7; E9PWG2_MOUSE/157-604; ER-Golgi trafficking TRAPP I complex 85 kDa subunit  ali follow..  9  3...............PM-----EQFSKLSQEQHRIQHNNDYSYPKWFIPNTLKY--------YVLLHDVTSGDEQRAESI--YEEMKQKYGLLKINSRAPNRKNSDSNLLSLDGLDNEVKVDGLPNNFRIHPLQIDQCGDPPNNTDGSESKSASSVHETKKASTAVIRGACLTLTDHDRIRQFIQEFT---FRGLLPHIEKTIRQLNDQ----------------------------------------------------------------------LISRKGLSRSLFSATKKWFSGSKVPEKSINELKNTSGLLYPPEAPELQIRKMADLCFLVQHYDLAYSCYHTAKKDFLNDQAMLYAAGALEMAAVSAFLQPGAPRP-------------------------------------------------YPAHYMDTAIQTYRDICKNM----------VLAERCVLLSAEILKSQSKYSEAAALLI---------------RLTSEDSDLRSALLLEQAAHCFINMKSPMVRKYAFHMILAG-FSKAGQKKHALRCYCQAMQVY.......................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 435
6 -10.800PF12862.7; APC5_SCHPO/263-353; Anaphase-promoting complex subunit 5  ali follow..  14  28..........................................................................................................................................................................................................................................................................................................................IMHSDEKVSYQYALLNLAMLQADFGCNEEALHAIEDTINTARESGDTACLNFALAWM................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................ 84
7 -10.500PF14874.6; Q4DUQ4_TRYCC/1589-1690; Flagellar-associated PapD-like  ali follow..  17  1...................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................VPTLSVMPSVLSFGRVIR--GNRYALPVVFTNTSTVPCR-YRVTLPTECKDILRVHYPRH--------------------------------FLAPGLTVMAQVEISGTQPLGAMSFSLNVTHEGGL------------IPVKVEIET............................................................................................................................................................................................................................................................................................................................................ 101
8 -10.300PF10633.9; Q67M97_SYMTH/263-339; NPCBM-associated, NEW3 domain of alpha-galactosidase  ali follow..  16  4.......................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................GRKNGVTLEVKNTGTTEITGINFASTLPP--------------------------------WTATFSPDSIDALAPGESRQVTVEVTPNSKALAGDYLVTLRARS................................................................................................................................................................................................................................................................................................................................................................... 77
9 -10.200PF15780.5; G3VKZ4_SARHA/34-131; Abnormal spindle-like microcephaly-assoc`d, ASPM-SPD-2-Hydin  ali follow..  22  21......................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................VGVSRTLPLVLDNPNEEGVEVSVARLPAADKGFSISPQS-CALQSKERISLSITWTPAKEGRVR............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. 83
10 -10.000PF13424.6; Q4DK03_TRYCC/687-760; Tetratricopeptide repeat  ali follow..  17  1...................................................................................................................................................................................................................................................................................................................................HQRPLQNYAQLKCQLGDMLSALSLQETELEIAKEFGDTRATSRCMGAIALT............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. 51
11 -9.330PF12371.8; A9UVP6_MONBE/19-102; Transmembrane protein 131-like  ali follow..  16  15......................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................LCKVAERVVTVVNG-NPRADLHLYSISSNSNDFHSSWFEHAVVAPGDNTTFTIAFMSETLGNITLLT.......................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 84
12 -9.050PF06933.11; O44418_CHIPA/1-756; Special lobe-specific silk protein SSP160  ali follow..  6  2........NIKVILVFFAQVAEGG----ISLLFSLFEVMVSVVFDVKSFT----SLSTPTCNSTVPSFATRVGGGRFS----------------TASFNMIAMISANVQAIQSGSGSTSGSSSSSTTSTSNSTTTTSNSTTTTTNSTTSSN----TSSGLTSSASVVSLIDTIAWVYQDSSVGIAYLMVSILALFYGQSVSAPPYPDLGIPALPANCSGPGVPQSVQIRAAIAYVNITIYFINMTGQQFEDLQGPVATDCGCPNTTSVAPLVLEWEAILAALQALANSTASANSTTSSNSTTTTTTNSTSTTTTNSTTTTNSTSSSNSSTIAGCIDISANFTIALQSLQALLLQESTCAPAL--SPCKPGKTASGCAKSGEKKVKRKARLEKMRAKCRRAVGNRMKGSMKKRVRSRAKKFGEAAKSGVRRYRKNIKYVYIPPVMASLNAYAALMASLSESISSQS.................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. 459
13 -9.000PF05753.14; Q9VUZ0_DROME/9-186; Translocon-associated protein beta (TRAPB)  ali follow..  12  10............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................CLSEDETRARLLVSKQILNKY---LVEKSDLLVRYTIFNVGSGAA--TKVRLVDSGFHPEAFDVVGGQPTAV---------------------------RIAPQTNFTHVLVVRGYFNFTAAEVSYKAVEESETLQLAVSS.......................................................................................................................................................................................................................................................................................................................................................... 124
FFAS is supported by the NIH grant R01-GM087218-01
1 4 2 3 4 1   jobs submitted since Jan 1, 2011
Comments and questions to: webmaster
Selected papers from Godzik Lab
Ying Zhang, Ines Thiele, Dana Weekes, Zhanwen Li, Lukasz Jaroszewski, Krzysztof Ginalski, Ashley Deacon, John Wooley, Scott Lesley, Ian Wilson, Bernhard Palsson, Andrei Osterman, Adam Godzik. Three-Dimensional Structural View of the Central Metabolic Network of Thermotoga maritima. Science. 2009 Sep 18;325(5947):1544-9.

Mayya Sedova, Mallika Iyer, Zhanwen Li, Lukasz Jaroszewski, Kai W Post, Thomas Hrabe, Eduard Porta-Pardo, Adam Godzik Cancer3D 2.0:: interactive analysis of 3D patterns of cancer mutations in cancer subsets. Nucleic Acids Research, gky1098 2018; Published on November 8 2018.

Bossy-Wetzel E, Barsoum MJ, Godzik A., Schwarzenbacher R, Lipton SA. Mitochondrial fission in apoptosis, neurodegeneration and aging. Curr Opin Cell Biol. 2003 Dec;15(6):706-16. Review.